State Street SPDR SandP Biotech ETF (XBI) |
| 135.72 3.67 (2.78%) 04-14 16:00 |
| Open: | 133.23 |
| High: | 136.4 |
| Low: | 133.03 |
| Volume: | 11,025,840 |
| Market Cap: | 7,652(M) |
| PE Ratio: | 0 |
| Exchange: | New York Stock Exchange Arca |
| Industry: | Asset Management |
| Sector: | Financial Services |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 159.32 |
| Resistance 1: | 136.40 |
| Pivot price: | 127.22 |
| Support 1: | 125.15 |
| Support 2: | 118.19 |
| 52w High: | 136.4 |
| 52w Low: | 73.94 |
T
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Tue, 14 Apr 2026
Citigroup, Morgan Stanley, CBRE Group And More On CNBC's 'Final Trades' - Benzinga
Sun, 12 Apr 2026
Roundview Capital LLC's State Street SPDR S&P Biotech ETF(XBI) Holding History - GuruFocus
Tue, 07 Apr 2026
XBI vs. IBB: The Biotech ETF Showdown That Analysts Say Has a Clear Winner in 2026 - 24/7 Wall St.
Fri, 03 Apr 2026
This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It. - AOL.com
Fri, 03 Apr 2026
This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It. - 24/7 Wall St.
Wed, 25 Mar 2026
Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now? - Yahoo Finance
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
